Novo Nordisk's CagriSema Underperforms Eli Lilly's Zepbound in Head-to-Head Obesity Trial
Novo Nordisk's next-generation obesity drug CagriSema achieved 23% weight reduction compared to 25.5% for Eli Lilly's tirzepatide in an 84-week trial, sending Novo shares down 15% and erasing over $400 billion in market value since 2024.